Search This Blog

Sunday, September 23, 2018

Ladenburg CEO Richard Lampen to Replace Phillip Frost as Chairman


Ladenburg Thalmann Financial Services Inc. (NYSE: LTS) announced today that its Board of Directors has appointed Richard Lampen, Ladenburg’s President and Chief Executive Officer, to serve as Chairman of the Board, replacing Dr. Phillip Frost. Adam Malamed, Ladenburg’s Executive Vice President and Chief Operating Officer, will join the Board of Directors.
Dr. Phillip Frost said, “I have decided to retire from the Ladenburg Board and will concentrate my efforts on OPKO Health and my philanthropic interests. As a long-term shareholder, I am confident in Ladenburg’s outlook and look forward to its continued growth and success.”
“We thank Phil for his service to Ladenburg and its shareholders over the past 14 years,” said Richard Lampen. “Ladenburg would not be where it is today without his many contributions, and his presence in the boardroom will be sorely missed.”
Mr. Lampen continued, “Our business is robust, and the company remains well-capitalized. Ladenburg’s book value exceeds $390 million, the Ladenburg entities hold approximately $250 million of cash, and the company is focused on building on its successes and delivering value to shareholders.”

Needle-free blood draws at last?


The dreaded needlestick in the healthcare environment is a source of nightmares for many.  People have dreamed about getting rid of needles for years, not only to help patients relax when getting their blood drawn, but also to keep healthcare workers safe.
But even though there is legislation on the books—the Needlestick Safety and Prevention Act of 2000 encourages the use of safety sheaths and retractable needles and requires healthcare facilities to evaluate new sharps safety devices annually—injuries from sharps and needlesticks continue to occur.

NEEDLE-FREE BLOOD DRAWS

University Hospitals in Cleveland, Ohio, announced in July that it has implemented the PIVO needle-free device from San Francisco–based Velano Vascular at UH Cleveland Medical Center for inpatient blood draws.
“As an institution, we continually look for innovative new technologies that improve the delivery and quality of care we provide,” Daniel I. Simon, MD, president of UH Cleveland Medical Center, says in a statement. “As caregivers, we strive to serve our patients in the most humane and personal way possible. This new procedure makes it possible for us to do both, eliminating the pain and anxiety associated with blood collection while advancing our own high standards and practices.”
Two other hospitals, Griffin Hospital in Derby, Connecticut and Brigham & Women’s Hospital in Boston, are also testing the PIVO device.
In typical practice, an IV needle is used to puncture the skin. That needle is then withdrawn and replaced with a plastic tube that becomes soft and almost noodle-like over time. While a “noodle” is fine for injecting fluids and medications into a patient, it’s bad for drawing fluids out of a patient, as the negative pressure of suction causes the tube’s soft walls to collapse. Also, clots that form at the ends of the IV catheter can disrupt the blood testing process.
The PIVO uses a narrower-gauge, stiffer tube inside the existing IV tube for collecting a blood draw. The device is used once and then thrown away, after which the IV catheter is reattached to the bag containing whatever fluids were being delivered to the patient prior to the blood draw. PIVO allows practitioners to extract high-quality blood samples from the vein, eliminating the need for multiple needlesticks.
The device was created by Velano Chief Executive and co-founder Eric M. Stone and President Pitou Devgon, MD. Velano won FDA approval for the PIVO in 2015; it has also obtained two U.S. patents for the device, according to published reports, with additional applications outstanding in the U.S. and abroad. Velano has publicly acknowledged receiving a total of $8.5 million in investments to improve the device.
The adoption of PIVO at UH’s flagship academic campus follows evaluation of the technology and the procedure in multiple UH Cleveland Medical Center inpatient units, the hospital said in a statement.
“Our evaluation and collaboration proved that PIVO delivers high-quality blood draws in an elegant manner that enhances the patient-practitioner relationship, reduces rejected blood samples, and provides an alternative to accessing central lines for blood collection,” said Cheryl O’Malley, vice president of patient care services and nursing at UH Cleveland Medical Center. “We are excited to bring this procedure and technology to our entire academic hospital, especially for our most vulnerable patients like those at UH Rainbow Babies & Children’s.”

SAFER SHARPS SLOW TO EVOLVE

More than 400 million blood draws occur annually in hospitals in the U.S., informing as much as 70% of all clinical decisions. Many of these are conducted in a hospital setting on patients that receive as many as three blood draws daily. This number of daily draws can increase dramatically for the 30% of U.S. hospital patients that are classified as “difficult venous access,” or DVA, due to obesity, age, or disease.
Stone is a Northeast Ohio native and former UH Rainbow Babies & Children’s Hospital patient. “As a chronic disease sufferer and over the course of multiple hospitalizations as a teenager, I developed a clinical fear of needles,” said Stone. “My personal experience as a patient has informed our person-centered mission at Velano to enable more humane care. Coming full circle, back to UH and Rainbow, to make this technology a national standard of care will enable our children and their parents to have their blood drawn in a gentler fashion.”
It may have important benefits for healthcare staff, too.
In July 2017, the Houston-based group International Safety Center released surveillance data from hospitals in 2015 that showed a marked increase in injuries from sharps and needlesticks sustained by training physicians (i.e., residents and interns) compared to 2014, and an overall increase in injuries sustained in the operating room, along with an unexpected decrease in the use of safety-engineered medical devices.
And, according to OSHA, up to 5.6 million workers in the U.S. are at risk of exposure to bloodborne pathogens, such as HIV and hepatitis, because they use needles and other sharps like scalpels as part of their everyday job. In fact, every year, about 1 million workers in hospital and clinic settings suffer a needlestick or other sharps-related injury.
One well-known example of this is the experience of nurse Karen Daley. In 1998, she was working in the ED at a Boston-area hospital and was stuck by a needle protruding from a full sharps container. As a result, Daley contracted both HIV and Hepatitis and had to end her career in the ED. She has since become an advocate for needlestick safety and lobbied for the 2000 Needlestick Safety and Prevention Act. She is also former president of the American Nurses Association.
Safe in Common, a nonprofit organization based in York, Pennsylvania, issued a list of guidelines in 2013 that serves as a “wish list” of attributes for sharps safety. Established in 2010, SIC is an organization of healthcare professionals and advocates that work to raise awareness of needlestick injuries and save lives of healthcare workers.
The guidelines, titled “The Top Ten Golden Rules of Safety,” were released at the Association for Professionals in Infection Control and Epidemiology conference in Fort Lauderdale, Florida. Specifically, the guidelines seek to make needlestick injuries a “never event,” an incident so rare that it almost never happens, by lobbying for sharps that are easy to use in even the most distracting environments. In addition, safety devices should be activated automatically so that they’re safe and easy to use with one hand. Sharps should also be “rendered safe prior to removal or exposure to the environment,” should not cause additional harm or discomfort to the patient, and should not add to the already-high cost of medical waste.

India launches ‘Modicare’, world’s biggest health scheme


India on Sunday launched the world’s biggest health insurance scheme which Prime Minister Narendra Modi said would cover some 500 million poor people.
The programme, dubbed “Modicare”, promises health cover worth 500,000 rupees ($6,900) to every poor family to treat serious ailments.
The scheme is expected to cost the central and 29 state governments $1.6 billion per year in total. Funding will be increased gradually according to demand.
Modi handed medical cards out at the launch in Ranchi, capital of the eastern state of Jharkhand, calling it a historic day for India.
He called the scheme “a big step towards providing good quality and accessible healthcare to the poor of India. Over 100 million families will benefit.”
India’s overburdened public health system is plagued by a shortage of hospitals and doctors and most people use private clinics and hospitals if they can afford to.
But a private consultation can cost 1,000 rupees ($15), a huge sum for millions living on less than $2 a day.
More than 60 percent of the average family’s spending goes on medicines and healthcare, the government estimates.
Experts have praised the latest programme but say it should have included primary day-to-day healthcare instead of just secondary and tertiary care for more serious and long term treatment.
“Modicare does not extend to primary , which, we believe, is the weakest link in the provision of public health in India,” Rajiv Lall and Vivek Dehejia of the IDFC Institute think-tank said in a column for the Mint newspaper.
“The crucial point is that poorly delivered primary care inevitably increases the burden on  and finance at the secondary and tertiary levels down the line,” they said.

ERs See Rise In Syndrome Related To Marijuana Use


With more people using medical marijuana and recreational marijuana, there’s a condition that’s popping up in emergency rooms across the country.
It’s called Cannabinoid Hyperemesis Syndrome, or CHS, and the symptoms are not pretty.
“Painful cramping, vomiting occurring. It can happen every few weeks, every few months, last a few days and be incredibly uncomfortable,” said Dr. Michael Lynch of the Pittsburgh Poison Control Center at UPMC.
The vomiting can be so severe that many go to the hospital, needing fluids to rehydrate. Dr. Lynch said it’s still unknown what causes CHS, but researchers are looking at certain receptors that are affected by marijuana use.
According to the National Center for Biotechnology Information, marijuana is a complex plant with hundreds of chemical entities, adding to the complications of trying to determine what leads to CHS.
“We need time and obviously, study. And that’s going to be really important,” said Dr. Lynch.
It’s also unknown if forms of medical marijuana could cause CHS. Dr. Lynch emphasized the reason it will take time to determine is because many of the patients don’t develop symptoms until years after daily, chronic marijuana use.
There’s another commonality among patients.
“Frequently asking or wanting to go take hot showers because they’ve learned that will at least temporarily help them to feel better,” Dr. Lynch said.
But that relief is only temporary and there’s only one permanent treatment solution.
“The only way, if you’re someone who suffers from this, that you can ease and stop the suffering is to discontinue use,” Dr. Lynch said.
And even then, it can take a while for symptoms to dissipate.
“Marijuana is stored in fat all throughout our body. We know, even from testing, we can find it for weeks or more after someone’s last used it,” Dr. Lynch said.
Dr. Lynch said it’s important for people to be honest about their medical and social history in order to get a quicker diagnosis.

‘Game-changing’ technique to create babies from skin cells just stepped up


Scientists in Japan made progress recently in the quest to combat infertility, creating the precursor to a human egg cell in a dish from nothing but a woman’s blood cells. The research is an important step toward what scientists call a “game-changing” technology that has the potential to transform reproduction.
The primitive reproductive cell the scientists created is not a mature egg, and it cannot be fertilized to create an embryo. But researchers have already created eggs out of mouse tail cells and fertilized them to produce viable pups, so outside scientists said the research is on track to one day achieve human “in vitro gametogenesis” — a method of creating eggs and sperm in a dish.
“The successful accomplishment of the same in human [cells] is just a matter of time. We’re not there yet, but this cannot be denied as a spectacular next step,” said Eli Adashi, a former dean of medicine and biological sciences at Brown University who was not involved in the study. “Considering how difficult this has been in a human, [this new study] in a way broke the ice. When I saw this, I said to myself, ‘you know, this [field] is moving.’ ”
For years, scientists have been working to harness the regenerative potential of stem cells for different purposes, hoping they could be used to regenerate heart muscle or the brain cells lost in Parkinson’s disease. The discovery more than a decade ago that ordinary skin or blood cells can be reprogrammed into stem cells capable of developing into any type of tissue in the body has been one of the most tantalizing frontiers in biomedical research.
Mitinori Saitou, a stem cell researcher at Kyoto University in Japan who led the new study published in Science, has been working for years to apply that approach to egg and sperm cells. In the new experiment, he created stem cells from human blood cells and then guided them to develop into “primordial” reproductive cells at a very early stage of egg development. His team was able to keep the cells alive for four months by incubating them in a dish with mouse ovary cells. The cells developed into oogonia, precursors of mature egg cells that appear during the first trimester of pregnancy.
“I think this is an important step, but it’s one of several steps that will be necessary before eggs and sperm made from stem cells will be usable,” said Henry Greely, director of the center for law and the biosciences at Stanford University, and author of “The End of Sex and the Future of Human Reproduction.” “This is farther than anyone has ever gotten with human eggs before, but it is not yet an egg.”
Many scientists think it is a matter of when, not if, scientists will be able to create a mature egg — and with that will come a slew of basic safety and mind-boggling ethics questions. Harvard Medical School stem cell biologist Toshi Shioda pointed out that even after the technical challenges are overcome, a major concern will be the possibility of cancers or other diseases that could arise in any babies created from such an egg.
If the safety questions are answered, the societal and ethical questions begin to multiply. Could someone unknowingly be made a parent without their permission, if someone creates reproductive cells from a cheek smear? Could women’s biological clocks be turned back or eliminated if the need for egg harvesting ends? Would the ease of creating many eggs make in vitro fertilization far more routine? And could the ease of creating eggs, in turn, allow parents to more routinely screen out genetic diseases?
Scientists say the time to start deliberating about those scenarios, educating the public and talking about oversight is now.
“By the time we see the next science paper . . . that will not be the optimal time to talk about it. There will be potential backlash, adverse actions, that are motivated by who knows what — political, religious, other considerations, that would put this technology in a state of abeyance,” Adashi said, adding the technology could be a “game-changer” and the biggest breakthrough in human reproduction since IVF was developed.
In the meantime, Shioda said there will be direct applications for this technology much sooner than any far-off revolution in reproduction.
If researchers create large numbers of developing reproductive cells, they can systematically test and understand how medicines or environmental exposures affect those eggs. Scientists could better understand how chemotherapy, toxic chemicals or power plant radiation affects reproductive cells.
Saitou said his next goal is to develop a method to bring the oogonia further through development, perhaps by incubating them with embryonic ovarian cells from a human instead of a mouse.
While the research sets off ethical questions, in vitro fertilization was controversial when it was first developed. Scientists who do work in this area say they receive frequent emails from people who cannot conceive children and wish the technology were ready.
“If we could do this, if it works and is safe, hundreds of thousands or millions of couples in the U.S. could have genetically related babies when they can’t today,” Greely said. “There’s no obvious reason that it won’t work. But the basic thing I’ve learned about biology is it has a way of surprising us.”

Luye Pharma Alzheimer’s Patch Treatment to be launched in China


Luye Pharma Group has announced that import registration procedures for one of the company’s core central nervous system (CNS) products, ‘Rivastigmine Transdermal Patches’, have been completed and approved by the China National Medical Products Administration, with the expectation that the drug will soon launch in China.
Outside of China, the drug is available in more than 20 countries worldwide, for years a strong sales performer. Luye Pharma hopes to continue to strengthen its product line in the field of CNS treatment, further enhancing its core competitiveness and global operational capabilities.
Developed on the transdermal drug delivery R&D platform at Luye Pharma AG, the German subsidiary of Luye Pharma, Rivastigmine patches are used for the treatment of mild to moderate Alzheimer’s disease. Luye Pharma has long been engaged in the research and development of advanced drug delivery technologies, such as transdermal drug delivery systems, microspheres and liposomes, reaching advanced international standards in these fields.
Today, Alzheimer’s disease is the fourth leading threat to the health of the elderly after cardiovascular diseases, malignancies, and stroke. According to the World Alzheimer’s Disease Report, there were 46.8 million patients worldwide suffering from dementia in 2015, with the overall cost of dementia in 2018 expected to reach USD 1 trillion. The average prevalence of Alzheimer’s disease in people over the age of 65 in China is 6.6%, meaning the number of patients living with Alzheimer’s disease in China is estimated to be over 6 million.
Alzheimer’s disease can cause memory impairments, cognitive abnormalities, executive function disorders, aphasia and other complications which seriously impact the quality of life and familial relations of the elderly. Moreover, Alzheimer’s disease is widely acknowledged to be one of the most difficult diseases to treat, with the number of new drugs approved by the FDA remaining very low. Rivastigmine is currently used as a first-line treatment for mild to moderate Alzheimer’s disease.
Luye Pharma’s Rivastigmine patch provides another delivery option for patients experiencing problems with drug compliance or swallowing (active ingredients are instead absorbed by the body through the skin), avoiding any gastrointestinal discomfort caused by oral medications and dysphagia in some patients. Compared to traditional tablets, they can effectively reduce the required frequency of administration and fluctuations in levels of medication in the blood, providing a smooth and sustained drug release. In addition, Luye Pharma’s Rivastigmine patches are designed for once-daily administration, thus improved ease of use and patient compliance can greatly alleviate caregiver burdens and effectively reduce allocation of public resources.
The company’s Rivastigmine patch product and its formulation methods are protected under multiple patents worldwide. The product is already available in more than 20 countries around the globe, including the United States, ten European countries comprising Germany, Portugal, France, Italy, the Netherlands, Denmark, Finland, Norway, Sweden and Switzerland, as well as Israel and Thailand, among others. Due to its clinical value and success at addressing patient needs, sales have been very strong in the global markets. According to IQVIA data, in 2017, total sales in the European and American markets for Luye Pharma’s Rivastigamine patches reached USD 520 million. In the U.S. market, the company’s Rivastigmine patches represent 44% of sales by volume of all transdermal patch products.
In addition to Rivastigmine single-day patches, multi-day patch products are also under clinical development by Luye Pharma AG.

TransEnterix Acquires Assets, IP, R&D Team from MST Medical Surgery Tech


  • Adds advanced surgical image analytics technology capabilities to Senhance digital laparoscopy platform
  • Establishes Israel-based R&D Center
TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today announced that it has acquired substantially all of the assets of MST Medical Surgery Technologies Ltd. (“MST”), an Israel medical technology company, in a cash and stock transaction with a total consideration, further described below. MST is a leader in the field of surgical technology, having developed a software-based image analytics platform powered by advanced visualization, scene recognition, artificial intelligence, machine learning and data analytics.
“Adding innovative, novel technological capabilities to Senhance is a critical part of our long-term strategy as we work towards digitizing the interface between the surgeon and the patient,” said Todd M. Pope, President and CEO of TransEnterix. “The addition of the MST technology to our Senhance platform will increase the effectiveness of surgeons, making procedures quicker and less error-prone, leading to better outcomes for the patient.”
“We are very excited to be partnering with TransEnterix, one of the leaders in surgical robotics who is pioneering the industry with their Senhance platform,” said Motti Frimer, CEO of MST. “The Senhance is a fantastic product with incredible potential, and we have a shared vision with TransEnterix of providing digital laparoscopy to better equip surgeons with innovative technologies that enhance their abilities, providing better quality, more consistent outcomes.”
Strategic Rationale
The addition of MST’s technology, IP portfolio, and R&D team supports and accelerates TransEnterix’s vision to leverage its Senhance Surgical System to deliver digital laparoscopy, thereby increasing control in the surgical environment and reducing surgical variability.
  • Innovative Surgical Technology Portfolio: MST’s technology and software engine will help accelerate Senhance platform innovation to meaningfully advance the benefits of digital laparoscopy to patients, surgeons and operating rooms globally. Key components of MST’s technology include advanced visualization, scene recognition, artificial intelligence, machine learning and data analytics.
  • Established R&D Center: Provides immediate access to an established R&D center in Israel, with a core team of experienced engineers. In addition, the R&D center allows the Company to tap into talent from one of the world’s top technology hubs.
Transaction Structure
TransEnterix acquired from MST substantially all of its assets, which includes technology and intellectual property, and will transfer MST’s Israeli-based R&D team to a newly formed subsidiary, TransEnterix Israel, Ltd.
The transaction will be financed with a combination of cash and stock, delivered in two separate tranches. At the closing of the transaction, MST will receive approximately $5.8 million in cash and 3,150,000 shares of TransEnterix common stock. The second tranche of $6.6 million, payable in cash or stock, is to be paid within one year of closing. The timing and form of payment of the second tranche is at TransEnterix’s sole discretion.
Conference Call
TransEnterix, Inc. will host a conference call tomorrow, Monday, September 24, 2018 at 8:00 AM ET to discuss this acquisition. To listen to the conference call on your telephone, please dial (844) 804-5261 for domestic callers or (612) 979-9885 for international callers, and reference the “Acquisition of Medical Surgical Technologies Ltd” conference call, approximately ten minutes prior to the start time. To access the live audio webcast with presentation slides or archived recording, use the following link http://ir.transenterix.com/events.cfm. The presentation materials for the conference call will be available for download at 7:00 AM ET at http://ir.transenterix.com/events.cfm. The replay will be available on TransEnterix’s website for approximately 90 days after the conference call.